Patients
Our Commitment
At Zura Bio, patients are at the heart of everything we do.
Our mission is to transform the lives of those living with severe autoimmune and inflammatory conditions by delivering breakthrough treatments that offer real hope and lasting impact.
We are pursuing an innovative approach to dual-pathway biology with the aim of redefining what’s possible for patients whose needs go unmet by conventional therapies. With a relentless focus on innovation, our goal is to bring meaningful change to their daily lives and deliver treatments that make a real difference where it matters most.
Clinical Trials
The TibuSURE trial is evaluating tibulizumab in patients with systemic sclerosis.
TRIAL STATUS: Initiated
TRIAL INFORMATION: TibuSURE is a multicenter, randomized, placebo-controlled, Phase 2 study of tibulizumab in participants with systemic sclerosis
Learn more about tibulizumab →
Expanded Access Policy
Zura Bio is a clinical-stage immunology company dedicated to developing innovative dual-pathway antibody therapies for autoimmune and inflammatory diseases. We are currently conducting clinical trials to assess the safety and effectiveness of our investigational product candidates. These trials are essential for gathering the evidence required to obtain regulatory approval, which is necessary before these therapies can be made widely available to patients.
At this time, Zura Bio does not offer access to its investigational products through an Expanded Access program (also known as “compassionate use”). We believe that participation in our clinical trials is the most appropriate and preferred way for patients to access these investigational treatments. Consistent with the 21st Century Cures Act, we may revise this policy at any time.
If you are a physician interested in learning more about our investigational therapies, please contact us at medinfo@zurabio.com.